JWH-364

Add links
Source: Wikipedia, the free encyclopedia.
JWH-364
Legal status
Legal status
Identifiers
  • [5-(4-Ethylphenyl)-1-pentyl-1H-pyrrol-3-yl](1-naphthyl)methanone
JSmol)
  • CCCCCN1C=C(C=C1C2=CC=C(C=C2)CC)C(=O)C3=CC=CC4=CC=CC=C43
  • InChI=1S/C28H29NO/c1-3-5-8-18-29-20-24(19-27(29)23-16-14-21(4-2)15-17-23)28(30)26-13-9-11-22-10-6-7-12-25(22)26/h6-7,9-17,19-20H,3-5,8,18H2,1-2H3 checkY
  • Key:VJWBAPGRMUZBEH-UHFFFAOYSA-N checkY

JWH-364 ([5-(4-Ethylphenyl)-1-pentyl-1H-pyrrol-3-yl](1-naphthyl)methanone) is a

synthetic cannabinoid from the naphthoylpyrrole family which acts as an agonist of the CB1 (Ki = 34 ± 3nM) and CB2 (Ki = 29 ± 1nM) receptors, with a slight selectivity for the latter. JWH-364 was first synthesized in 2006 by John W. Huffman and colleagues to examine the nature of ligand binding to the CB1 receptor.[1]

Legality

In the United States JWH-364 is not federally scheduled, although some states have passed legislation banning the sale, possession, and manufacture of JWH-364.[2][3][4][5]

In Canada, JWH-364 and other naphthoylpyrrole-based cannabinoids are Schedule II controlled substances under the Controlled Drugs and Substances Act.

In the United Kingdom, JWH-364 and other naphthoylpyrrole-based cannabinoids are considered Class B drugs under the Misuse of Drugs Act 1971.

See also

References

  1. PMID 16889960
    .
  2. ^ 21 U.S.C. § 812: Schedules of controlled substances
  3. ^ "The 2020 Florida Statutes". www.leg.state.fl.us. Retrieved 20 August 2021.
  4. ^ "Arizona Revised Statutes Title 13. Criminal Code § 13-3401". www.azleg.gov. Retrieved 20 August 2021.
  5. ^ "California Code, Health and Safety Code - HSC § 11357.5". Findlaw.
Retrieved from "https://en.wikipedia.org/w/index.php?title=JWH-364&oldid=1132890635"